{
    "nct_id": "NCT04319757",
    "official_title": "A Phase I, Open Label, Dose Escalation Study of ACE1702 Cell Immunotherapy in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors",
    "inclusion_criteria": "* Signed informed consent\n* Subjects must be ≥ 18 years of age ( ≥ 20 years of age for Taiwan site)\n* Subject with advanced or metastatic solid tumors that is not amenable to surgical resection and is not eligible or has refused other approved therapeutic options that have demonstrated clinical benefit.\n* Histologically confirmed HER2 expression.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1\n* Measurable or non-measurable evaluable disease according to RECIST 1.1\n* Adequate hematologic and end-organ function at baseline\n* Oxygen saturation via pulse oxygenation ≥ 90% at rest on room air\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Untreated central nervous system (CNS) metastases\n* Multiple primary malignancies\n* Clinically significant cardiovascular disease such as New York Heart Association (NYHA) cardiac disease (class III or greater)\n* Pregnant or lactating female\n* Serious, uncontrolled medical disorder that, in the opinion of the Investigator, would impair the ability of the subject to receive study treatment\n* History of autoimmune or immune mediated symptomatic disease\n* Any anti-cancer chemotherapy or targeted small molecule therapy, or experimental therapy/device within 4 weeks or 5 half-lives of the drug prior to planned start of the study",
    "miscellaneous_criteria": ""
}